Filing Details

Accession Number:
0001209191-18-042890
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-07-17 18:01:56
Reporting Period:
2018-07-16
Accepted Time:
2018-07-17 18:01:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
873303 Sarepta Therapeutics Inc. SRPT Pharmaceutical Preparations (2834) 930797222
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1529297 T David Howton 215 First Street, Suite 415
Cambridge MA 02142
Svp, General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-07-16 3,096 $13.71 37,967 No 4 M Direct
Common Stock Disposition 2018-07-16 3,096 $136.46 34,871 No 4 S Direct
Common Stock Acquisiton 2018-07-16 9,056 $13.71 43,927 No 4 M Direct
Common Stock Disposition 2018-07-16 9,056 $136.46 34,871 No 4 S Direct
Common Stock Acquisiton 2018-07-16 37,848 $13.90 72,719 No 4 M Direct
Common Stock Disposition 2018-07-16 37,848 $136.46 34,871 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2018-07-16 3,096 $13.71 3,096 $13.71
Common Stock Stock option (right to buy) Disposition 2018-07-16 9,056 $13.71 9,056 $13.71
Common Stock Stock option (right to buy) Disposition 2018-07-16 37,848 $13.90 37,848 $13.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,431 2017-02-28 2026-02-28 No 4 M Direct
10,090 2017-02-28 2026-02-28 No 4 M Direct
27,159 2016-02-27 2025-02-27 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 15, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.